Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04800809 · ClinicalTrials.gov registry record
The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria
A clinical trial of Stroke and Sickle Cell Disease, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 350
- Enrollment target
- 3
- Study locations
NCT04800809: Completed study of Stroke and Sickle Cell Disease, sponsored by Vanderbilt University Medical Center.
NCT04800809 is a study of Stroke and Sickle Cell Disease that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 350 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04800809, a study of Stroke and Sickle Cell Disease, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 350 participants
- Enrollment target
- 3
- Study locations
Study Summary
Sickle Cell Anemia (SCA) occurs in 300,000 newborns per year in the world, with 150,000 affected births in Nigeria, alone. With improvement in survival for children with SCA in both high- and low-resource countries, neurological morbidity is an emerging significant public health challenge, particularly in countries with a high rate of sickle cell disease (SCD). Both silent cerebral infarcts (SCI) and overt strokes result in significant neurological morbidity and premature death. Five NIH-funded randomized controlled trials (RCT) demonstrated that regular blood transfusion or hydroxyurea therapy are efficacious treatments for primary and secondary stroke prevention in children with SCA. Despite the observation that at least 99% of children with SCA in high-resource settings reach adulthood, and approximately 60% of adults will experience one or more strokes (\~50% with SCI and \~10% with overt strokes) and the high disease-burden in Nigeria, the prevalence and incidence rates of new and recurrent stroke (overt and silent strokes)have not been collected systematically in children and young adults (16-25 years old) with SCA. In the last decade, there has been growing use of stroke registries in economically advanced nations, particularly for epidemiological purposes of trend analysis, clinical effectiveness, compliance to guidelines, assessment of implementation, adoption of novel techniques, and quality improvement process. For the first time in clinical centers in Nigeria, the Investigators will conduct an observational epidemiological study to document the prevalence and track the incidence of new and recurrent strokes in children and young adults with SCD. The Investigators will create a stroke registry referred to as the Afolabi Stroke Registry for Children and Young Adults with Sickle Cell Disease in Nigeria. The overall purpose of the stroke registry is to document the natural history of SCD in a low-resource setting and to improve the quality of the care of chi
Primary Outcome
To determine the incidence of stroke recurrence rates in children and young adults with SCD living in Nigeria. For this purpose, an electronic online registry will be created. All children and young adults ages between 5 to 26 years old with SCD who are being followed at the participating sites in Nigeria will be consented to enroll to the Afolabi SCD Stroke Registry in Nigeria. The Investigators will collect and document all acute neurological events (stroke and transient ischemic attacks (TIA)
Conditions Studied
Interventions
- OTHER This study does not entail offering any intervention; all data collected will be based on standard of care.
Study Locations (3)
Other
- Jamil Galadanci - Kano
- Aminu Kano Teaching Hospital - Kano
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2023-12-31 |
What the finished NCT04800809 record still lists
NCT04800809 is an observational study that tracks outcomes without assigning an intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (97% lower).
The record links to 6 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which This study does not entail offering any intervention; all data collected will be based on standard of care. is the first listed.
NCT04800809 reports a single indexed study location in Other, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04800809 about?
NCT04800809 is a clinical study titled "The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria". Sickle Cell Anemia (SCA) occurs in 300,000 newborns per year in the world, with 150,000 affected births in Nigeria, alone. With improvement in survival for children with SCA in both high- and low-resource countries, neurological morbidity is an emerging significant public health challenge, particula...
What is the current status of trial NCT04800809?
This trial is currently completed. The enrollment target is 350 participants. The study started on 2020-04-01. Estimated completion is 2023-12-31.
What conditions does trial NCT04800809 study?
This clinical trial studies the following conditions: Stroke, Sickle Cell Disease, Sickle Cell Anemia, Neurologic Manifestations, Sickle Cell Anemia in Children.
What interventions are being tested in trial NCT04800809?
The interventions under investigation include: This study does not entail offering any intervention; all data collected will be based on standard of care. (OTHER).
Who is sponsoring clinical trial NCT04800809?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04800809 being conducted?
This trial has 3 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04800809's enrollment target sits among peer trials
350 71st of 454 higher than 382 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SLEEPR Study: SLEep Effects on Post-stroke Rehabilitation
RECRUITING
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Genetic and Environmental Risk Factors for Hemorrhagic Stroke
RECRUITING
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI